BTIG Maintains Buy on MDxHealth, Lowers Price Target to $2

Benzinga Newsdesk www.benzinga.com Negative 60.1%

Neg 60.1% Neu 0% Pos 0%

BTIG analyst Mark Massaro maintains MDxHealth (NASDAQ:MDXH) with a Buy and lowers the price target from $4 to $2.

Comments

No comments yet. Be the first!